Kairos Pharma shares surge 11.00% after-hours on positive Phase 2 prostate cancer trial results for ENV105 showing 86% clinical benefit and no severe toxicities.

Kairos Pharma surged 11.00% in after-hours trading following the release of positive interim results from its Phase 2 clinical trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer. The trial demonstrated clinical benefit in 86% of treated patients, with a median progression-free survival of 13.7 months, no dose-limiting toxicities, and manageable side effects. These findings, presented at the ESMO conference, highlight the potential of ENV105 to improve disease control and tolerability compared to existing therapies. The company also outlined 2026 milestones, including enrollment completion for the Phase 2 trial and continued development of other candidates. The data underscore Kairos’s progress in addressing unmet needs in oncology, fueling investor optimism about its pipeline and therapeutic innovation.